文献速递淋巴瘤

伊布替尼联合R-CHOP治疗非生发中心B细胞型弥漫大B细胞淋巴瘤的随机III期试验

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2019-03-22

这项双盲III期研究将838例未经治疗的非生发中心B细胞型弥漫大B细胞淋巴瘤患者随机分配至伊布替尼联合R-CHOP组或安慰剂联合R-CHOP组。伊布替尼联合R-CHOP在ITT人群和ABC亚组均未改善无事件生存,预设分析显示治疗与年龄存在显著交互作用:<60岁患者联合伊布替尼改善EFS、PFS和OS,≥60岁患者毒性增加且R-CHOP给药受损、结局更差。

要点

  • 伊布替尼联合R-CHOP在ITT人群(HR 0.934)和ABC亚组(HR 0.949)均未改善EFS,研究未达主要终点。
  • <60岁患者中伊布替尼联合R-CHOP改善EFS(HR 0.579)、PFS(HR 0.556)和OS(HR 0.330)。
  • ≥60岁患者中伊布替尼联合R-CHOP增加严重不良事件(63.4% vs 38.2%)并降低完成≥6周期R-CHOP比例(73.7% vs 88.8%),EFS、PFS和OS更差。

核心结论

  • 研究在ITT或ABC人群中未达到主要终点。
  • <60岁患者中伊布替尼联合R-CHOP改善EFS、PFS和OS且安全性可控。
  • ≥60岁患者中伊布替尼联合R-CHOP与毒性增加相关,导致R-CHOP给药受损和结局更差。
  • 需要进一步研究。

研究设计与样本

  • 双盲III期随机对照试验,按1:1随机分配至伊布替尼(560 mg每日口服)联合R-CHOP组或安慰剂联合R-CHOP组。
  • 共838例未经治疗的非生发中心B细胞型DLBCL患者随机分配,伊布替尼联合R-CHOP组419例,安慰剂联合R-CHOP组419例。
  • 主要终点为ITT人群和ABC DLBCL亚组的无事件生存(EFS)。
  • 次要终点包括无进展生存(PFS)、总生存(OS)和安全性。

主要发现

  • 中位年龄62.0岁,可评估患者中75.9%为ABC亚型,基线特征均衡。
  • 伊布替尼联合R-CHOP未改善ITT人群EFS(HR 0.934)或ABC人群EFS(HR 0.949)。
  • 预设分析显示治疗与年龄存在显著交互作用。
  • <60岁患者中伊布替尼联合R-CHOP改善EFS(HR 0.579)、PFS(HR 0.556)和OS(HR 0.330),严重不良事件略增(35.7% vs 28.6%),完成≥6周期R-CHOP比例相似(92.9% vs 93.0%)。
  • ≥60岁患者中伊布替尼联合R-CHOP使EFS、PFS和OS更差,严重不良事件增加(63.4% vs 38.2%),完成≥6周期R-CHOP比例降低(73.7% vs 88.8%)。

临床怎么用

  • 研究未达到主要终点,作者认为需要进一步研究。

局限性

  • 需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL. PATIENTS AND METHODS: Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. RESULTS: A total of 838 patients were randomly assigned to ibrutinib plus R-CHOP (n = 419) or placebo plus R-CHOP (n = 419). Median age was 62.0 years; 75.9% of evaluable patients had ABC subtype disease, and baseline characteristics were balanced. Ibrutinib plus R-CHOP did not improve EFS in the ITT (hazard ratio [HR], 0.934) or ABC (HR, 0.949) population. A preplanned analysis showed a significant interaction between treatment and age. In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%). In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%). CONCLUSION: The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes. Further investigation is warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Younes A, Sehn LH, Johnson P, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019. PMID: 30901302. doi:10.1200/JCO.18.02403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。